Simone Botti
Directeur/Membre du Conseil chez Scenic Biotech BV
Profil
Simone Botti is currently a Director at VarmX BV, a Non-Executive Director at Scenic Biotech BV, and a Partner at INKEF Capital BV.
Previously, she was the Chief Executive Officer of Metabomed Ltd.
from 2013 to 2020 and the Chief Executive Officer & Director of Neviah Genomics Ltd.
Postes actifs de Simone Botti
| Sociétés | Poste | Début |
|---|---|---|
Scenic Biotech BV
 Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Directeur/Membre du Conseil | - |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Directeur/Membre du Conseil | - |
INKEF Capital BV
 INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Private Equity Investor | 01/01/2022 |
Anciens postes connus de Simone Botti
| Sociétés | Poste | Fin |
|---|---|---|
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Directeur Général | 09/09/2020 |
Neviah Genomics Ltd.
 Neviah Genomics Ltd. Pharmaceuticals: MajorHealth Technology Neviah Genomics Ltd. develops novel biomarkers for the prediction of drug-induced toxicity. It identifies biomarkers for the prediction of drug-induced toxicity. The firm offers involving cell harvest and culture, compound exposure, mRNA expression analysis and multi-parameter mathematical computation. The company was founded in 2012 and is headquartered in Yavne, Israel. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
INKEF Capital BV
INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Finance |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Health Technology |
Neviah Genomics Ltd.
Neviah Genomics Ltd. Pharmaceuticals: MajorHealth Technology Neviah Genomics Ltd. develops novel biomarkers for the prediction of drug-induced toxicity. It identifies biomarkers for the prediction of drug-induced toxicity. The firm offers involving cell harvest and culture, compound exposure, mRNA expression analysis and multi-parameter mathematical computation. The company was founded in 2012 and is headquartered in Yavne, Israel. | Health Technology |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Commercial Services |